{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:08:26Z","timestamp":1789632506055,"version":"build-2803163510"},"reference-count":102,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.1001\/jamaneurol.2020.2494","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T15:17:56Z","timestamp":1595863076000},"page":"1308","source":"Crossref","is-referenced-by-count":34,"title":["New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention"],"prefix":"10.1001","volume":"77","author":[{"given":"Aristeidis H.","family":"Katsanos","sequence":"first","affiliation":[{"name":"Division of Neurology, McMaster University, Hamilton, Ontario, Canada"},{"name":"Population Health Research Institute, Hamilton, Ontario, Canada"},{"name":"Hamilton Health Sciences, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Hart","sequence":"additional","affiliation":[{"name":"Division of Neurology, McMaster University, Hamilton, Ontario, Canada"},{"name":"Population Health Research Institute, Hamilton, Ontario, Canada"},{"name":"Hamilton Health Sciences, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"nrv200004r1","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/archneurol.2010.190","article-title":"Persistence with stroke prevention medications 3 months after hospitalization.","volume":"67","author":"Bushnell","year":"2010","journal-title":"Arch Neurol"},{"issue":"8","key":"nrv200004r2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.amjmed.2013.01.033","article-title":"Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis.","volume":"126","author":"Kumbhani","year":"2013","journal-title":"Am J Med"},{"issue":"1","key":"nrv200004r3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/STROKEAHA.115.011248","article-title":"Rates, predictors, and outcomes of early and late recurrence after stroke: the North Dublin Population Stroke study.","volume":"47","author":"Callaly","year":"2016","journal-title":"Stroke"},{"issue":"1","key":"nrv200004r4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1212\/WNL.0000000000001099","article-title":"Optimal combination secondary prevention drug treatment and stroke outcomes.","volume":"84","author":"Park","year":"2015","journal-title":"Neurology"},{"issue":"16","key":"nrv200004r5","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMoa1412981","article-title":"One-year risk of stroke after transient ischemic attack or minor stroke.","volume":"374","author":"Amarenco","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"nrv200004r6","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1161\/01.STR.0000190118.02275.33","article-title":"Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis.","volume":"36","author":"Touz\u00e9","year":"2005","journal-title":"Stroke"},{"issue":"7","key":"nrv200004r7","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1212\/WNL.62.7.1036","article-title":"Aspirin: it\u2019s hard to beat.","volume":"62","author":"Anderson","year":"2004","journal-title":"Neurology"},{"issue":"10042","key":"nrv200004r8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(16)30468-8","article-title":"Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials.","volume":"388","author":"Rothwell","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"nrv200004r9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(08)70094-2","article-title":"Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.","volume":"7","author":"Huang","year":"2008","journal-title":"Lancet Neurol"},{"issue":"4","key":"nrv200004r10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.STR.0000063141.24491.50","article-title":"Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study, a randomized, double-blind, multicenter trial.","volume":"34","author":"Mat\u00edas-Guiu","year":"2003","journal-title":"Stroke"},{"issue":"1","key":"nrv200004r11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"nrv200004r12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA.","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"nrv200004r13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack.","volume":"375","author":"Johnston","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"nrv200004r14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.410420606","article-title":"A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin.","volume":"42","author":"The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group","year":"1997","journal-title":"Ann Neurol"},{"issue":"9","key":"nrv200004r15","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMoa1204133","article-title":"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.","volume":"367","author":"Benavente","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"nrv200004r16","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1161\/STROKEAHA.113.004251","article-title":"Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques.","volume":"45","author":"Amarenco","year":"2014","journal-title":"Stroke"},{"issue":"13","key":"nrv200004r17","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa043033","article-title":"Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.","volume":"352","author":"Chimowitz","year":"2005","journal-title":"N Engl J Med"},{"issue":"23","key":"nrv200004r18","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source.","volume":"378","author":"Hart","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"nrv200004r19","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for prevention of stroke after embolic stroke of undetermined source.","volume":"380","author":"Diener","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"nrv200004r20","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa011258","article-title":"A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.","volume":"345","author":"Mohr","year":"2001","journal-title":"N Engl J Med"},{"issue":"7","key":"nrv200004r21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/1747493019830307","article-title":"The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: rationale and design.","volume":"14","author":"Johnston","year":"2019","journal-title":"Int J Stroke"},{"key":"nrv200004r22","doi-asserted-by":"crossref","first-page":"l2211","DOI":"10.1136\/bmj.l2211","article-title":"Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial.","volume":"365","author":"Wang","year":"2019","journal-title":"BMJ"},{"issue":"23","key":"nrv200004r23","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMoa1802712","article-title":"Five-year risk of stroke after TIA or minor ischemic stroke.","volume":"378","author":"Amarenco","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"nrv200004r24","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease.","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"nrv200004r25","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.118.035864","article-title":"Stroke outcomes in the COMPASS Trial.","volume":"139","author":"Sharma","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"nrv200004r26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamaneurol.2019.2984","article-title":"Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the COMPASS trial.","volume":"77","author":"Perera","year":"2019","journal-title":"JAMA Neurol"},{"issue":"8","key":"nrv200004r28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.13005","article-title":"Factor XI and contact activation as targets for antithrombotic therapy.","volume":"13","author":"Gailani","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"1","key":"nrv200004r29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/ATVBAHA.118.310960","article-title":"Advances in antithrombotic therapy.","volume":"39","author":"Weitz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"nrv200004r30","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events.","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"issue":"8","key":"nrv200004r31","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency.","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"issue":"3","key":"nrv200004r32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/QC259F09UNMKVP0R","article-title":"Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events.","volume":"126","author":"Yang","year":"2006","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"nrv200004r33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000297966","article-title":"Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study.","volume":"29","author":"Suri","year":"2010","journal-title":"Cerebrovasc Dis"},{"issue":"5","key":"nrv200004r34","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/j.thromres.2011.06.010","article-title":"Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events.","volume":"128","author":"Undas","year":"2011","journal-title":"Thromb Res"},{"issue":"3","key":"nrv200004r35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1084\/jem.20052458","article-title":"Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis.","volume":"203","author":"Kleinschnitz","year":"2006","journal-title":"J Exp Med"},{"issue":"11","key":"nrv200004r36","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/STROKEAHA.118.022792","article-title":"Genetically determined FXI (Factor XI) levels and risk of stroke.","volume":"49","author":"Gill","year":"2018","journal-title":"Stroke"},{"issue":"10","key":"nrv200004r37","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.119.040180","article-title":"Novel drug targets for ischemic stroke identified through mendelian randomization analysis of the blood proteome.","volume":"140","author":"Chong","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"nrv200004r40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack.","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"nrv200004r41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1910355","article-title":"A comparison of two LDL cholesterol targets after ischemic stroke.","volume":"382","author":"Amarenco","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"nrv200004r42","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"nrv200004r43","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"nrv200004r44","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"nrv200004r45","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.118.002162","article-title":"Large-scale phenome-wide association study of PCSK9 variants demonstrates protection against ischemic stroke.","volume":"11","author":"Rao","year":"2018","journal-title":"Circ Genom Precis Med"},{"issue":"3","key":"nrv200004r46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0038-1676863","article-title":"PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention.","volume":"119","author":"Paciullo","year":"2019","journal-title":"Thromb Haemost"},{"issue":"6","key":"nrv200004r47","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1161\/STROKEAHA.106.480657","article-title":"Lipoprotein (a) and stroke: a meta-analysis of observational studies.","volume":"38","author":"Smolders","year":"2007","journal-title":"Stroke"},{"issue":"1","key":"nrv200004r48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1161\/STROKEAHA.116.014436","article-title":"Lipoprotein(a) levels and recurrent vascular events after first ischemic stroke.","volume":"48","author":"Lange","year":"2017","journal-title":"Stroke"},{"issue":"4","key":"nrv200004r49","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/ATVBAHA.118.311857","article-title":"Lipoprotein(a) and risk of ischemic stroke in the REGARDS study.","volume":"39","author":"Arora","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"nrv200004r50","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke.","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"nrv200004r51","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","article-title":"Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis.","volume":"242","author":"Nave","year":"2015","journal-title":"Atherosclerosis"},{"key":"nrv200004r52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.08.013","article-title":"Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults.","volume":"253","author":"Beheshtian","year":"2016","journal-title":"Atherosclerosis"},{"issue":"1","key":"nrv200004r53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1212\/01.WNL.0000132637.30287.B4","article-title":"High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis.","volume":"63","author":"Arenillas","year":"2004","journal-title":"Neurology"},{"issue":"4","key":"nrv200004r54","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41588-018-0058-3","article-title":"Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.","volume":"50","author":"Malik","year":"2018","journal-title":"Nat Genet"},{"issue":"1","key":"nrv200004r55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/CIRCGENETICS.110.958371","article-title":"Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.","volume":"4","author":"Hopewell","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"issue":"12","key":"nrv200004r56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114519","article-title":"Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers.","volume":"9","author":"Arsenault","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"nrv200004r57","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"issue":"23","key":"nrv200004r58","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.jacc.2009.02.041","article-title":"Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.","volume":"53","author":"Fraley","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"nrv200004r59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jacc.2008.02.066","article-title":"Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.","volume":"52","author":"Choi","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"nrv200004r60","article-title":"Statin therapy increases lipoprotein(a) levels.","author":"Tsimikas","year":"2019","journal-title":"Eur Heart J"},{"issue":"17","key":"nrv200004r61","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1161\/CIRCULATIONAHA.117.031356","article-title":"LPA variants are associated with residual cardiovascular risk in patients receiving statins.","volume":"138","author":"Wei","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"nrv200004r62","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jacl.2019.04.005","article-title":"PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: a pooled analysis of nine randomized-controlled studies of alirocumab.","volume":"13","author":"Bruckert","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"8","key":"nrv200004r64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11883-019-0792-8","article-title":"Antisense oligonucleotides targeting lipoprotein(a).","volume":"21","author":"Langsted","year":"2019","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"nrv200004r65","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease.","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"nrv200004r66","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1097\/01.mjt.0000433937.07244.e1","article-title":"Colchicine: new insights to an old drug.","volume":"22","author":"Stack","year":"2015","journal-title":"Am J Ther"},{"issue":"7347","key":"nrv200004r67","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis.","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"issue":"4","key":"nrv200004r68","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/CIRCRESAHA.116.310527","article-title":"How common is residual inflammatory risk?","volume":"120","author":"Ridker","year":"2017","journal-title":"Circ Res"},{"issue":"1","key":"nrv200004r69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jjcc.2015.02.002","article-title":"Anti-inflammatory and immune-modulatory therapies for preventing atherosclerotic cardiovascular disease.","volume":"66","author":"Yamashita","year":"2015","journal-title":"J Cardiol"},{"issue":"8","key":"nrv200004r70","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/heartjnl-2015-308542","article-title":"Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis.","volume":"102","author":"Hemkens","year":"2016","journal-title":"Heart"},{"issue":"17","key":"nrv200004r71","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/archinte.165.17.1987","article-title":"Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (Colchicine for Recurrent Pericarditis) trial.","volume":"165","author":"Imazio","year":"2005","journal-title":"Arch Intern Med"},{"issue":"15","key":"nrv200004r72","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.115.017611","article-title":"Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study.","volume":"132","author":"Deftereos","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"nrv200004r73","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease.","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"26","key":"nrv200004r74","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction.","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"nrv200004r75","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/ene.14198","article-title":"Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis.","volume":"27","author":"Katsanos","year":"2020","journal-title":"Eur J Neurol"},{"issue":"6","key":"nrv200004r76","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/STROKEAHA.107.507988","article-title":"Critical cap thickness and rupture in symptomatic carotid plaques: the Oxford Plaque Study.","volume":"39","author":"Redgrave","year":"2008","journal-title":"Stroke"},{"issue":"21","key":"nrv200004r77","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy.","volume":"368","author":"Libby","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"nrv200004r79","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/STROKEAHA.119.024157","article-title":"Inflammation, autoimmunity, infection, and stroke: epidemiology and lessons from therapeutic intervention.","volume":"51","author":"Parikh","year":"2020","journal-title":"Stroke"},{"issue":"1","key":"nrv200004r80","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dci17-0057","article-title":"Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? reflections from a Diabetes Care editors\u2019 expert forum.","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"nrv200004r81","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"nrv200004r82","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.13955","article-title":"Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.","volume":"22","author":"Husain","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"nrv200004r83","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(19)30423-1","article-title":"The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.","volume":"8","author":"Gerstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"nrv200004r84","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-020-09813-4","article-title":"GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis.","author":"Malhotra","year":"2020","journal-title":"J Neurol"},{"issue":"6","key":"nrv200004r85","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2337\/db15-1141","article-title":"Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis.","volume":"65","author":"Cameron-Vendrig","year":"2016","journal-title":"Diabetes"},{"issue":"3","key":"nrv200004r86","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.pcd.2019.01.003","article-title":"Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.","volume":"13","author":"Alfayez","year":"2019","journal-title":"Prim Care Diabetes"},{"issue":"2","key":"nrv200004r87","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","article-title":"Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis.","volume":"48","author":"Lee","year":"2017","journal-title":"Stroke"},{"issue":"5","key":"nrv200004r88","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.117.030458","article-title":"Pioglitazone prevents stroke in patients with recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke).","volume":"137","author":"Yaghi","year":"2018","journal-title":"Circulation"},{"issue":"9891","key":"nrv200004r89","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(13)60852-1","article-title":"Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.","volume":"382","author":"Benavente","year":"2013","journal-title":"Lancet"},{"key":"nrv200004r90","doi-asserted-by":"crossref","first-page":"i708","DOI":"10.1136\/bmj.i708","article-title":"Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention After Stroke\u2014Blood Pressure) randomised controlled trial.","volume":"352","author":"Mant","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"nrv200004r91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164608","article-title":"Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke: main results from the pilot \u201cPrevention of Decline in Cognition After Stroke Trial\u201d (PODCAST) randomised controlled trial.","volume":"12","author":"Bath","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"nrv200004r92","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaneurol.2019.2167","article-title":"Effect of standard vs intensive blood pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis.","volume":"76","author":"Kitagawa","year":"2019","journal-title":"JAMA Neurol"},{"issue":"1","key":"nrv200004r93","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/HYPERTENSIONAHA.116.08485","article-title":"Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials.","volume":"69","author":"Katsanos","year":"2017","journal-title":"Hypertension"},{"issue":"1","key":"nrv200004r94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5853\/jos.2014.16.1.27","article-title":"Intracranial atherosclerosis: current understanding and perspectives.","volume":"16","author":"Bang","year":"2014","journal-title":"J Stroke"},{"issue":"4","key":"nrv200004r95","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.mehy.2005.05.017","article-title":"A possible explanation for the racial difference in distribution of large-arterial cerebrovascular disease: ancestral European settlers evolved genetic resistance to atherosclerosis, but confined to the intracranial arteries.","volume":"65","author":"Mak","year":"2005","journal-title":"Med Hypotheses"},{"issue":"1","key":"nrv200004r96","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/01.STR.26.1.14","article-title":"Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: the Northern Manhattan Stroke Study.","volume":"26","author":"Sacco","year":"1995","journal-title":"Stroke"},{"issue":"8","key":"nrv200004r97","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/archneur.62.8.1232","article-title":"Mechanisms of recurrence in subtypes of ischemic stroke: a hospital-based follow-up study.","volume":"62","author":"Shin","year":"2005","journal-title":"Arch Neurol"},{"issue":"16","key":"nrv200004r98","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/CIRCULATIONAHA.114.011147","article-title":"Cause and mechanisms of intracranial atherosclerosis.","volume":"130","author":"Ritz","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"nrv200004r99","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/jnnp.2004.054403","article-title":"Inflammatory markers, rather than conventional risk factors, are different between carotid and MCA atherosclerosis.","volume":"76","author":"Bang","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"nrv200004r100","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1161\/STR.0000000000000116","article-title":"Prevention of stroke in patients with silent cerebrovascular disease: a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"48","author":"Smith","year":"2017","journal-title":"Stroke"},{"issue":"7","key":"nrv200004r101","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1474-4422(07)70170-9","article-title":"Silent brain infarcts: a systematic review.","volume":"6","author":"Vermeer","year":"2007","journal-title":"Lancet Neurol"},{"issue":"4","key":"nrv200004r102","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1161\/STROKEAHA.119.027569","article-title":"Dabigatran treatment of acute noncardioembolic ischemic stroke.","volume":"51","author":"Butcher","year":"2020","journal-title":"Stroke"},{"key":"nrv200004r27","unstructured":"ClinicalTrials.gov. Combination antithrombotic treatment for prevention of recurrent ischemic stroke in intracranial atherosclerotic disease (NCT04142125). Published October 29, 2019. Accessed February 2, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04142125"},{"key":"nrv200004r38","unstructured":"ClinicalTrials.gov. Oral factor XIa inhibitor for the prevention of new ischemic stroke in patients receiving aspirin and clopidogrel following acute ischemic stroke or transient ischemic attack (TIA) (AXIOMATIC-SSP). Published December 6, 2018. Accessed February 8, 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03766581."},{"key":"nrv200004r39","unstructured":"ClinicalTrials.gov. Study to gather information about proper dosing and safety of the oral FXIa inhibitor BAY 2433334 in patients following a recent noncardioembolic ischemic stroke which occurs when a blood clot has formed somewhere in the human body (but not in the heart) travelled to the brain (PACIFIC-STROKE). Published March 11, 2020. Accessed March 14, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04304508"},{"key":"nrv200004r63","unstructured":"ClinicalTrials.gov. PCSK9 inhibition in patients with symptomatic intracranial atherosclerosis (PINNACLE). Published April 25, 2018. Accessed December 2, 2019. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03507374?"},{"key":"nrv200004r78","unstructured":"ClinicalTrials.gov. Colchicine for Prevention of Vascular Inflammation in Non-Cardioembolic stroke (CONVINCE)\u2014a randomised clinical trial of low-dose colchicine for secondary prevention after stroke. Published September 13, 2016. Accessed February 8, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02898610"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2768702\/jamaneurology_katsanos_2020_rv_200004_1601489517.46604.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T18:49:00Z","timestamp":1602528540000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2768702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":102,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2020.2494","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}